Currently, two PARPi agents (olaparib and talazoparib) have received US Food and Drug Administration (FDA) approval for use in patients with gBRCA-mutated HER2 (erb-b2 receptor tyrosine kinase 2)-negative advanced breast cancer previously treated with chemotherapy and/or endocrine therapy, respectively [14]. This evidence concerns the gene ERBB2 and breast cancer.